Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Trevi Therapeutics Inc 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 USA

www.trevitherapeutics.com Employees: 26 P: 203-304-2499

Sector:

Medical

Description:

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut.

Key Statistics

Overview:

Market Capitalization, $K 1,447,717
Enterprise Value, $K 1,413,617
Shares Outstanding, K 128,230
Annual Sales, $ 0 K
Annual Net Income, $ -47,910 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -11,800 K
EBIT, $ -51,350 K
EBITDA, $ -51,200 K
60-Month Beta 0.91
% of Insider Shareholders 18.30%
% of Institutional Shareholders 95.76%
Float, K 104,764
% Float 81.70%
Short Interest 13,652
Short Float 10.65%
Short Volume Ratio 0.61

Growth:

1-Year Return 182.96%
3-Year Return 384.55%
5-Year Return 280.13%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 79.39%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.08 on 11/13/25
Next Earnings Date 03/17/26
Earnings Per Share ttm -0.37
EPS Growth vs. Prev Qtr 11.11%
EPS Growth vs. Prev Year 38.46%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

TRVI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -31.23%
Return-on-Assets % -29.32%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 7.17
Book Value/Share 1.56
Interest Coverage -2.95
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar